Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time. PerkinElmer’s ProSense® imaging agents are protease activatable NIR fluorescent probes that are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation. ProSense is available in 3 formats; 680, 750 EX, and 750 FAST.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
ProSense 750 FAST is in our family of “Smart” cathepsin probes, which become fluorescent only after enzymatic cleavage. ProSense 750 FAST offers faster activation after injection; it can be imaged at earlier times for optimized work flow, or for applications such as acute inflammation models. 4-24h imaging at 750 nm.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||ProSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).
Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory mediators, activate mast cells and epithelial cells and stimulate mucus secretion, ultimately leading to airway obstruction. The incidence and severity of asthma is increasing worldwide, elevating the need for clinically relevant in vivo animal models that can be used to improve the understanding of asthma biology and the development of effective therapeutics. Here we illustrate the use of PerkinElmer’s FMT® 2500LX Quantitative Pre-clinical Imaging System in combination with ProSense® 680 Fluorescent Pre-clinical Imaging Agent, a near-infrared, protease-activatable agent, for the noninvasive in vivo imaging and quantitation of pulmonary inflammation.
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.
ProSense 750 FAST activatable fluorescent imaging agent
ProSense® 750 FAST is part of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.